(2S,3R,4R,5S)-2-[(1R)-1,2-Dihydroxyethyl]-5-[(2S,3R,4S,5S)-5-[(1R)-1,2-dihydroxyethyl]-2-[(2R,3R,4S,5S)-5-[(1R)-1,2-dihydroxyethyl]-2,4-dihydroxyoxolan-3-yl]oxy-4-hydroxyoxolan-3-yl]oxyoxolane-3,4-diol

Term ID

CHEBI:151904

Synonyms

beta-D-galacto-hexofuranosyl-(1->2)-beta-D-galacto-hexofuranosyl-(1->2)-beta-D-galacto-hexofuranose
Galf(b1-2)Galf(b1-2)b-Galf
WURCS=2.0/1,3,2/[a2112h-1b_1-4]/1-1-1/a2-b1_b2-c1

Definition

References

GlyGen:G50036ZG
GlyTouCan:G50036ZG

Ontology

ChEBI ( EBI )

Relationships

is a type of: glycoside

glycoside Show first 5 Terms

Phenotype

Phenotype resulting from (2S,3R,4R,5S)-2-[(1R)-1,2-Dihydroxyethyl]-5-[(2S,3R,4S,5S)-5-[(1R)-1,2-dihydroxyethyl]-2-[(2R,3R,4S,5S)-5-[(1R)-1,2-dihydroxyethyl]-2,4-dihydroxyoxolan-3-yl]oxy-4-hydroxyoxolan-3-yl]oxyoxolane-3,4-diol

Phenotype where environments contain (2S,3R,4R,5S)-2-[(1R)-1,2-Dihydroxyethyl]-5-[(2S,3R,4S,5S)-5-[(1R)-1,2-dihydroxyethyl]-2-[(2R,3R,4S,5S)-5-[(1R)-1,2-dihydroxyethyl]-2,4-dihydroxyoxolan-3-yl]oxy-4-hydroxyoxolan-3-yl]oxyoxolane-3,4-diol

Phenotype modified by environments containing (2S,3R,4R,5S)-2-[(1R)-1,2-Dihydroxyethyl]-5-[(2S,3R,4S,5S)-5-[(1R)-1,2-dihydroxyethyl]-2-[(2R,3R,4S,5S)-5-[(1R)-1,2-dihydroxyethyl]-2,4-dihydroxyoxolan-3-yl]oxy-4-hydroxyoxolan-3-yl]oxyoxolane-3,4-diol

Human Disease Model